Comments
Jubilant Discovery Services Inc., a US based subsidiary of Jubilant Life Sciences Company, has entered into a drug discovery alliance with Janssen Pharmaceutica N.V. to deliver preclinical candidates to Janssen. The alliance is set to span an initial period of 3 years and will focus on multiple targets in the area of neuroscience.
Under the terms of the alliance agreement, Janssen will transfer ongoing efforts on selected drug discovery targets to Jubilant. Jubilant shall then carry out the research services and deliver preclinical candidates to Janssen for possible further development and commercialisation. In addition to receiving research funding, Jubilant may also be eligible to receive milestones and royalties should Janssen successfully develop and commercialise the candidates.
Mr Sri Mosur, CEO & President, Global Drug Discovery & Development, Jubilant said: “The collaboration will utilise Jubilant’s global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centres. We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry".
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.